GNGiulia De Napoli

Giulia De Napoli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giulia De Napoli has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chiara Baldovini

    Department of Pathology, Cardiovascular and Cardiac Transplant Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    1 shared publication
  • Diana Ferraro

    Dipartimento di Neuroscienze, Ospedale Civile di Baggiovara, Azienda Ospedaliera-Università di Modena, Modena, Italy

    1 shared publication
  • Enrico Gotti

    Cardiology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy

    1 shared publication
  • Francesca Vitetta

    Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy

    1 shared publication
  • Krzysztof Smolik

    Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy

    1 shared publication
  • Luisa Di Sciascio

    Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    1 shared publication

Latest Publications

  • Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis

    by Giulia De Napoli, Enrico Gotti, Chiara Baldovini, Luisa Di Sciascio, Francesca Vitetta, Krzysztof Smolik, Martina Cardi, Diana Ferraro

    A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and worsened over 10 days. A thorough diagnostic evaluation, including blood tests, coronary artery angiography, cardiac magnetic resonance imaging, and endomyocardial biopsy excluded ischemic or infectious causes of myocardial damage. Although cardiac complications have not previously been reported with ocrelizumab, this case suggests the drug may rarely cause reversible severe cardiac dysfunction and highlights the importance of vigilance for cardiotoxicity in people with multiple sclerosis.